Case reports

Serotonin syndrome induced by anti-parkinsonism drugs:a case report

Expand
  • 1. Department of Neurology, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
    2. Department of Pharmacy, Beijing Hospital; National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences; Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application(Beijing Hospital), Beijing 100730, China

Received date: 2021-08-02

  Online published: 2023-11-17

Abstract

Serotonin syndrome (SS) is an adverse drug reaction characterized by neuromuscular hyperexcitability that is mild in most cases but can be life-threatening in some cases. This paper reports a case of a 87-year-old man with Parkinson’s disease who was hospitalized due to pulmonary infection and fever. The clinical symptoms were improved after treatment. Subsequently, his condition fluctuated, including high fever, sweating, disturbance of consciousness, high muscle tone and elevated creatine kinase. After combining his clinical manifestations with his history of concomitant medication, the doctors found that the patient had overdosed on selegiline and had an adverse reaction with anti-infective drug linezolid. The patients was diagnosed having SS promptly and was treated actively and properly, including discontinuation of related medications, and physical cooling, extensive fluid rehydration, and symptomatic supportive treatment. Thus the patient’s condition was effectively controlled within 24 hours. The symptoms were basically improved 3 days after onset and completely relieved 5 days after onset. Prevention is the key point to SS, and clinicians should strengthen their awareness.

Cite this article

WU Dongdong, LI Shuhua, SU Wen, LIU Yinghong, CHEN Haibo, CHEN Di . Serotonin syndrome induced by anti-parkinsonism drugs:a case report[J]. Journal of Diagnostics Concepts & Practice, 2023 , 22(03) : 303 -305 . DOI: 10.16150/j.1671-2870.2023.03.15

References

[1] WERNEKE U, TRUEDSON-MARTINIUSSEN P, WIKSTR?M H, et al. Serotonin syndrome: a clinical review of current controversies[J]. J Integr Neurosci, 2020, 19(4):719-727.
[2] DUNKLEY EJ, ISBISTER GK, SIBBRITT D, et al. The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity[J]. QJM, 2003, 96(9):635-642.
[3] PRAKASH S, ADROJA B, PAREKH H. Serotonin syndrome in patients with headache disorders[J]. BMJ Case Rep, 2017, 2017:bcr2017221383.
[4] HéBANT B, GUILLAUME M, DESBORDES M, et al. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient[J]. Rev Neurol (Paris), 2016, 172(12):788-789.
[5] FRYKBERG R G, GORDON S, TIERNEY E, et al. Linezolid-associated serotonin syndrome. a report of two cases[J]. J Am Podiatr Med Assoc, 2015, 105(3):244-248.
[6] KATUS L E, FRUCHT S J. Management of serotonin syndrome and neuroleptic malignant syndrome[J]. Curr Treat Options Neurol, 2016, 18(9):39.
[7] WANG R Z, VASHISTHA V, KAUR S, et al. Serotonin syndrome: preventing, recognizing, and treating it[J]. Cleve Clin J Med, 2016, 83(11):810-817.
[8] WERNEKE U, JAMSHIDI F, TAYLOR D M, et al. Conundrums in neurology: diagnosing serotonin syndrome - a meta-analysis of cases[J]. BMC Neurol, 2016, 16:97.
Outlines

/